The search continues to find the holy grail in management of dry eye disease (DED). More than a decade has passed since the approval of Restasis (cyclosporine A) in the United States. An article “in press” in the American Journal of Ophthalmology titled: ”A Multicenter, Open-Label, 52-Week Study of 2% Rebamipide (OPC-12759) Ophthalmic Suspension in Patients with Dry Eye” in a Multicenter (17 sites), open-label single-arm study in Japan.
The purpose was to investigate the efficacy and safety of 2% rebamipide ophthalmic suspension administered 4 times daily for 52 weeks in patients with dry eye. The objective signs were fluorescein corneal staining score, lissamine green conjunctival staining score, and tear film break-up time, while subjective symptoms were dry eye-related ocular symptoms (foreign body sensation, dryness, photophobia, eye pain, and blurred vision). Rebamipide (Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan) is a mucosal protective agent with mucin secretagogue activity, and is marketed in Japan as an oral drug for the treatment of gastric mucosal disorders and gastritis.
Read more here.